Free shipping on all orders over $ 500

Lapatinib Ditosylate

Cat. No. M1802
Lapatinib Ditosylate Structure


Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mg USD 35  USD35 In stock
50mg USD 60  USD60 In stock
100mg USD 100  USD100 In stock
200mg USD 160  USD160 In stock
500mg USD 260  USD260 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Lapatinib Ditosylate is a selective and effective inhibitor of ErbB-2 and EGFR dual tyrosine kinases. ErbB-2 and EGFR dual tyrosine kinases are growth promoting factors that are over expressed in some breast cancer cell lines. Lapatinib inhibits the growth of both EGFR- and ErbB-2-overexpressing cells, whereas OSI-774 and Iressa which are EGFR selective inhibitors preferentially inhibit the growth of the EGFR-overexpressing cell lines. Research studies have reported that Lapatinib Ditosylate can inhibit breast cancer cell proliferation.

Product Citations
Customer Product Validations & Biological Datas
Source Proc Natl Acad Sci U S A (2018) . Figure 6. Lapatinib Ditosylate (AbMole BioScience)
Method i.v.
Cell Lines NSG mice
Concentrations 100 mg/kg
Incubation Time 5 d
Results Again, the single agents displayed modest activity, inhibiting tumor growth, whereas the combination shrank most of the tumors, similar to the BT-474 xenograft model.
Source Proc Natl Acad Sci U S A (2018) . Figure 5. Lapatinib Ditosylate (AbMole BioScience)
Method Western blotting
Cell Lines HCC-1419 and MDA-MB-453 cells
Concentrations 1 μM
Incubation Time 6, 12, and 24 h
Results To verify that both MCL-1:BIM and MCL-1:BAK complexes were disrupted by S63845, we immunoprecipitated MCL-1 complexes in lysates of the HER2-amplified breast cancer cells, HCC- 1419 and MDA-MB-453, following treatment with lapatinib, S63845 (at two concentrations of 300 nM and 1 μM), or their combination.
Source Proc Natl Acad Sci U S A (2018) . Figure 4. Lapatinib Ditosylate (AbMole BioScience)
Method Western blotting
Cell Lines MDA-MB-361 and BT-474 cells
Concentrations 1 μM
Incubation Time 24 h
Results Importantly, since HER2 inhibitors like lapatinib block ERK signaling in HER2-amplified breast cancers, it is likely that miR-4728 only has an antagonistic effect in the presence of HER2 inhibitors, while miR-4728 likely promotes tumorigenesis in the absence of HER2 inhibition.
Source Int J Pharm Pharm Sci (2016). Figure 3.Lapatinib (Abmole)
Method PH test
Cell Lines
Incubation Time 1~21 days
Results No significant changes in the vaginal pH were observed between control and treated animals throughout the three phases of the estrous cycle. Even though, on the 12th d, prolonged diestrus phase in treated group animals was evidenced with the vaginal pH as compared with the control mice [fig. 3].
Protocol (for reference only)
Cell Experiment
Cell lines HFF; BT474, MCF-7, N87, and CaLu-3; HN5, A-431, T47D, HB4a, and HB4a c5.2 cell lines
Preparation method In Vitro Growth Inhibition Assays For assessment of cell-based potency, cells were plated in 96-well Falcon plates (Becton Dickinson) in the growth media described above. Plating densities that resulted in logarithmic growth of vehicle-treated cells for the duration of the assay were used: HFF, 15,000 cells/cm2; BT474, MCF-7, N87, and CaLu-3, 30,000 cells/cm2; and HN5, A-431, T47D, HB4a, and HB4a c5.2, 10,000 cells/cm2. After 24 h, cells were exposed to compounds at the concentrations indicated in Fig. 2. HFF, BT474, HN5, and N87 cells were treated in low-glucose DMEM containing 5% FBS, 50 μg/ml gentamicin, and 0.3% v/v DMSO. MCF-7 cells were treated in 50% high-glucose DMEM, 50% low-glucose DMEM containing 5% FBS, 50 μg/ml gentamicin, and 0.3% v/v DMSO. T47D, A-431, and CaLu-3 cells were treated in 50% RPMI, 50% low-glucose DMEM containing 5% FBS, 50 μg/ml gentamicin, and 0.3% v/v DMSO. HB4a and HB4a c5.2 cells were treated in 50% DMEM, 50% RPMI 1640 supplemented with 5% FBS, 2.5 μg/ml hydrocortisone, 2.5 μg/ml insulin, 25 μg/ml hygromycin B, 50 μg/ml gentamicin, and 0.3% v/v DMSO. After 3 days, relative cell number was estimated using methylene blue staining. The media were removed, and 100 μl of 0.5% w/v methylene blue dissolved in 50% ethanol and 50% water were added to each well. Plates were washed by immersion in deionized water and allowed to air dry. 1% w/v n-lauroylsarcosine (100 μl) dissolved in PBS was added to each well, and plates were incubated for 30 min at room temperature. The absorbance at 620 nm was read in a Spectra (Tecan) microplate reader. Data were analyzed using curve-fitting macros written for Microsoft Excel. Concentrations with IC50 were interpolated using the method of Levenberg and Marquardt and this equation: y = Vmax × [1 − (xn/(Kn + xn))], where “K” is equal to IC50.
Concentrations 0~100 μM
Incubation time 3 days
Animal Experiment
Animal models CD-1 nude female mice were used for HN5 human tumor xenografts, C.B-17 SCID female mice were used for BT474 human tumor xenografts
Formulation sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10)
Dosages 30 or 100 mg/kg twice daily for 21 days
Administration p.o.
Chemical Information
Molecular Weight 925.46
Formula C29H26ClFN4O4S.2C7H8O3S
CAS Number 388082-78-8
Solubility (25°C) DMSO 90 mg/mL
Storage -20°C, sealed, protect from light
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Simonelli M, et al. Eur J Cancer. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.

[2] Bachelot T, et al. Lancet Oncol. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

[3] Jegg AM, et al. Breast Cancer Res Treat. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.

[4] de Jonge MJ, et al. Invest New Drugs. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.

[5] Rusnak DW, et al. Mol Cancer Ther. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Related EGFR/HER2 Products

Dosimertinib is a highly potent, selective, orally effective EGFR inhibitor for the study of non-small cell lung cancer.


JBJ-09-063 is an oral allogenic epidermal growth factor inhibitor currently in preclinical development for the study of non-small cell lung cancer (NSCLC) with epidermal growth factor L858R mutations.


BI-4142 is a HER2 exon 20 insertion mutant inhibitor being developed for non-small cell lung cancer (NSCLC), The IC50 value was 5 nM.


BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. BDTX-189 exhibits anticancer activity.


Naquotinib(ASP8273) is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity.

Abmole Inhibitor Catalog

Keywords: Lapatinib Ditosylate, Tykerb supplier, EGFR/HER2, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.